Inetetamab and chemotherapy for HER2-positive advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing an investigational drug called inetetamab (which targets HER2) combined with chemotherapy, and sometimes also an immunotherapy drug (PD-1/PD-L1 inhibitor). It aims to see if this combination helps people with advanced HER2-positive biliary tract cancer live longer and shrink their tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is HER2-positive (a specific protein on the cancer cells) and has spread (metastatic).
- You have not received any prior treatment that targets HER2.
- You have not had chemotherapy or other systemic treatment for advanced or recurrent disease.
- If your cancer returned after surgery, it must have been more than 6 months after the surgery (or after completion of post-surgery treatment).
- You have at least one tumor that can be measured, and your overall health is reasonably good (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This study tests a new drug called inetetamab for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see how well the drug works as a first treatment, potentially helping to control the cancer and improve quality of life.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
This trial tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) for people with advanced bile duct cancer that has a protein called HER2. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new combination of drugs for people with HER2-positive bile duct or gallbladder cancer that has grown after first treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Metastatic Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.